Nabi shareholder Chap-Cap may choose to recommend alternatives to company

By Lisa Kerner

Charlotte, N.C., June 15 - Nabi Pharmaceuticals investors led by Chap-Cap Activist Partners Master Fund, Ltd. purchased 2,733,295 shares of the company's stock between April 30 and June 14, priced from $4.78 to $5.91 per share, according to a schedule 13D filing with the Securities and Exchange Commission.

Chap-Cap and its affiliates have contacted the company in the past and may in the future consider a variety of different alternatives to achieve their goal of maximizing shareholder value, the filing stated. These alternatives include negotiated transactions, tender offers, proxy contests, consent solicitations or other actions.

The reporting persons beneficially own 3,978,867 shares, or 6.6%, of the Boca Raton, Fla., pharmaceutical company's outstanding stock.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.